Streetbeat News

HSTO

Histogen Inc

https://www.conatuspharma.com/

CEO

Steven Mento

Employees

Industry

Pharmaceutical Preparation Manufacturing

a regenerative medicine company based on naturally-produced products from newborn fibroblasts grown in a proprietary bioreactor. two product families - a proprietary liquid complex of embryonic-like proteins and growth factors, and a human extracellular matrix (ecm) material, exceltrix.

Open

0.21

Mkt cap

897K

Volume

High

0.21

P/E Ratio

-0.07

52-wk high

0.55

Low

0.21

Div yield

N/A

52-wk low

0.05

During Tuesday's intraday session, several healthcare stocks experienced significant movements. Gainers included Avinger, Elutia, Longeveron Inc. - Subscription Right, Applied Therapeutics, Streamline Health Solns, and PAVmed. Losers included UpHealth, Heart Test Laboratories, CareCloud, Histogen, Inhibikase Therapeutics, and MSP Recovery.

Portfolio Pulse from Benzinga Insights

September 19, 2023 | 5:31 pm

Histogen has announced that its Board of Directors approved a Plan of Dissolution, leading to a drop in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 2:31 pm

US stocks opened lower with the Dow Jones, NASDAQ, and S&P 500 all falling. Housing starts in the US fell 11.3% MoM to an annualized rate of 1.283 million in August, the lowest level since June 2020. Connexa Sports Technologies, Avinger, and Sezzle saw their shares rise, while Digital Transformation Opportunities Corp., Histogen, and Revance Therapeutics saw their shares fall.

Portfolio Pulse from Lisa Levin

September 19, 2023 | 1:59 pm

Histogen Inc.'s shares are set to resume trading at 4:35 p.m. ET.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2023 | 8:31 pm

Histogen has announced that its board has approved a complete liquidation and dissolution of the company, including the distribution of remaining cash to stockholders following an operational winddown. The company has discontinued all clinical development programs and reduced its workforce.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2023 | 8:06 pm

Shares of Histogen Inc. (HSTO) have been halted due to pending news.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2023 | 8:03 pm

Benzinga Insights has identified five value stocks in the healthcare sector based on quantified analysis. These include AcelRx Pharmaceuticals (ACRX), Organon (OGN), Histogen (HSTO), Allarity Therapeutics (ALLR), and Helius Medical Tech (HSDT). The companies have shown varying performance in their earnings per share, with some experiencing increases and others decreases.

Portfolio Pulse from Benzinga Insights

August 07, 2023 | 2:43 pm

Benzinga Insights has identified five value stocks in the healthcare sector that may be worth watching: Leafly Holdings, Voyager Therapeutics, Viatris, Dynavax Technologies, and Histogen. These companies have low price-to-earnings (P/E) multiples, indicating potential undervaluation. However, the risk with value stocks is that they may not rebound from their undervalued position.

Portfolio Pulse from Benzinga Insights

July 17, 2023 | 2:44 pm

The article lists the top gainers and losers in pre-market trading. Notable gainers include Akumin Inc., Mullen Automotive, and Micromobility.com Inc. On the other hand, Allarity Therapeutics, VBI Vaccines, and Tattooed Chef are among the biggest losers. The article also mentions several other companies that experienced significant changes in their stock prices.

Portfolio Pulse from Lisa Levin

July 06, 2023 | 12:04 pm

Histogen has decided to pause further development of its programs and commence exploring strategic alternatives. This decision has led to a rise in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 9:39 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.